Evidence map›Paper›PMID 40916834›Full record

ArticleClinical and experimental immunology2025

Expanded senescent CD8 T cells in IMID patients are associated with distinct inflammatory cytokines.

Marie Naigeon, Samuel Bitoun, Matthieu Roulleaux Dugage, Caroline de Oliveira, Caroline Berthot, Benjamin Besse, Aurélien Marabelle, François-Xavier Danlos, Xavier Mariette, Nathalie Chaput and 1 more

Abstract read
In one paragraph

Article in Clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marie NaigeonINSERM US23/CNRS UAR 3655, Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Samuel BitounRheumatology Department, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA, FHU CARE, Université Paris-Saclay, Le Kremlin Bicêtre, France.ORCID 0000-0003-0891-2269
Matthieu Roulleaux DugageINSERM US23/CNRS UAR 3655, Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Caroline de OliveiraINSERM US23/CNRS UAR 3655, Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Caroline BerthotINSERM US23/CNRS UAR 3655, Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Benjamin BesseDépartement de Médecine Oncologique, Université Paris-Saclay, Villejuif, France.ORCID 0000-0001-5090-8189
Aurélien MarabelleDépartement d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
François-Xavier DanlosDépartement d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Xavier MarietteRheumatology Department, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA, FHU CARE, Université Paris-Saclay, Le Kremlin Bicêtre, France.
Nathalie ChaputINSERM US23/CNRS UAR 3655, Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Gaetane NocturneRheumatology Department, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA, FHU CARE, Université Paris-Saclay, Le Kremlin Bicêtre, France.

Funding

Agence Nationale de la RechercheCentre National de la Recherche ScientifiqueFondation ArthritisFondation Malakoff MédéricGustave RoussyInstitut National de la Santé et de la Recherche Médicale
6 · The paper itself

Abstract

Using flow cytometry, we assessed circulating T4sen and T8sen proportions at baseline and 3 months after initiating anti-TNF treatment in RA and SpA patients using flow cytometry. Circulating levels of cytokines were measured at baseline. These parameters were associated with demographic variables and disease activity. T4sen and T8sen were compared between RA, SpA, SjD, healthy donors, and cancer patients. T8sen, but not T4sen, accumulated more in patients with IMIDs than in patients with lung cancer and healthy donors. CMV-seropositivity was associated with the accumulation of T8sen. T8sen were associated with high IL-6 in SpA patients and high IP-10 in SjD patients. Anti-TNF did not impact the T8sen proportion of RA and SpA patients. There was a trend toward an increase in T8sen in anti-TNF nonresponders after 3 months of treatment. Senescent CD8 T cells are enriched in IMID patients, suggesting that immune aging is a shared feature of chronic inflammatory diseases. The association between T8sen and distinct inflammatory cytokines underscores the potential role of senescence in shaping immune responses in IMIDs.

Indexed as

Arthritis, RheumatoidCD8-Positive T-LymphocytesCellular SenescenceCytokinesAdultAgedFemaleHumansMaleMiddle AgedTumor Necrosis Factor-alphaCytokinesTumor Necrosis Factor-alphaanti-TNFCD8 T cellsrheumatoid arthritissenescenceSjogren’s diseasespondyloarthritis

Identifiers

PMID40916834
PMCPMC12451446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.